Literature DB >> 27804111

Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis.

S Phatak1, S Chaurasia1, S K Mishra1, R Gupta1, V Agrawal2, A Aggarwal1, R Misra1.   

Abstract

B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) help in B cell activation, maintenance and plasma cell survival. B cell infiltration has been demonstrated in kidneys of patients with lupus nephritis (LN). Serum levels of BAFF and APRIL have shown inconsistent relationships with lupus disease activity. We evaluated urinary levels of BAFF and APRIL as biomarker for LN. Thirty-six patients with proliferative lupus nephritis (AN), 10 with active lupus without nephritis (AL) and 15 healthy controls (HC) were studied. APRIL and BAFF levels were measured in both serum and urine using enzyme-linked immunosorbent assay (ELISA). Urine levels were normalized for urinary creatinine excretion. Urine levels were correlated with conventional disease activity markers and histology. Levels were reassessed in 20 AN patients at 6 months after treatment with cyclophosphamide. Urinary APRIL (uAPRIL) and BAFF (uBAFF) levels were raised significantly in AN. uAPRIL, but not uBAFF, correlated moderately with renal Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in AN (r = 0·36, P < 0·05). On receiver operator curve (ROC) analysis, uBAFF and uAPRIL showed an area under the curve (AUC) of 0·825 and 0·781, respectively, in differentiating between nephritis and non-nephritis, which performed better than low C3, C4 and raised anti-dsDNA antibodies. There was no correlation of serum levels with uBAFF (r = 0·187, P = 0·261) and uAPRIL (r = 0·114, P = 0·494). uAPRIL levels reduced after treatment (mean 125 pg/mg to 36 pg/mg, P < 0·05). uBAFF levels reduced in 16 responders while two of four non-responders had increase in levels. Thus, uBAFF and uAPRIL are potential biomarkers of proliferative lupus nephritis.
© 2016 British Society for Immunology.

Entities:  

Keywords:  B cell; cytokines; systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 27804111      PMCID: PMC5290236          DOI: 10.1111/cei.12894

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Expressions of BAFF/BAFF receptors and their correlation with disease activity in Chinese SLE patients.

Authors:  L D Zhao; Y Li; M F Smith; J S Wang; W Zhang; F L Tang; X P Tian; H Y Wang; F C Zhang; D N Ba; W He; X Zhang
Journal:  Lupus       Date:  2010-11       Impact factor: 2.911

2.  Characterization of mononuclear cell subsets in renal cellular interstitial infiltrates.

Authors:  A Boucher; D Droz; E Adafer; L H Noël
Journal:  Kidney Int       Date:  1986-05       Impact factor: 10.612

3.  Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices.

Authors:  M Hegazy; H Darwish; H Darweesh; A El-Shehaby; Y Emad
Journal:  Clin Immunol       Date:  2010-02-08       Impact factor: 3.969

4.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

5.  Raised serum APRIL levels in patients with systemic lupus erythematosus.

Authors:  T Koyama; H Tsukamoto; Y Miyagi; D Himeji; J Otsuka; H Miyagawa; M Harada; T Horiuchi
Journal:  Ann Rheum Dis       Date:  2004-12-02       Impact factor: 19.103

6.  Longitudinal assessment of monocyte chemoattractant protein-1 in lupus nephritis as a biomarker of disease activity.

Authors:  Ranjan Gupta; Akhilesh Yadav; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2016-09-13       Impact factor: 2.980

Review 7.  Outcome criteria for lupus nephritis trials: a critical overview.

Authors:  D T Boumpas; J E Balow
Journal:  Lupus       Date:  1998       Impact factor: 2.911

8.  APRIL modulates B and T cell immunity.

Authors:  Jens V Stein; Marta López-Fraga; Fernando A Elustondo; Carla E Carvalho-Pinto; Dolores Rodríguez; Ruth Gómez-Caro; Joan De Jong; Carlos Martínez-A; Jan Paul Medema; Michael Hahne
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 9.  The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.

Authors:  D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma
Journal:  Arthritis Rheum       Date:  1996-03

10.  Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy.

Authors:  Ioannis Parodis; Agneta Zickert; Birgitta Sundelin; Magnus Axelsson; Jakob Gerhardsson; Elisabet Svenungsson; Vivianne Malmström; Iva Gunnarsson
Journal:  Lupus Sci Med       Date:  2015-01-22
View more
  9 in total

1.  High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene.

Authors:  M Marín-Rosales; A Cruz; D C Salazar-Camarena; E Santillán-López; N Espinoza-García; J F Muñoz-Valle; M G Ramírez-Dueñas; E Oregón-Romero; G Orozco-Barocio; C A Palafox-Sánchez
Journal:  Clin Exp Med       Date:  2019-02-11       Impact factor: 5.057

2.  Protein and functional isoform levels and genetic variants of the BAFF and APRIL pathway components in systemic lupus erythematosus.

Authors:  Pilar Ortiz-Aljaro; Marco Antonio Montes-Cano; José-Raúl García-Lozano; Virginia Aquino; Rosario Carmona; Javier Perez-Florido; Francisco José García-Hernández; Joaquín Dopazo; María Francisca González-Escribano
Journal:  Sci Rep       Date:  2022-07-02       Impact factor: 4.996

3.  Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers.

Authors:  David Aguirre-Valencia; Lady J Ríos-Serna; Iván Posso-Osorio; Juan Naranjo-Escobar; Daniel López; Vanessa Bedoya-Joaqui; Ivana Nieto-Aristizábal; Andrés M Castro; Lorena Díaz-Ordoñez; Erika P Navarro; María Claudia Barrera; Alex Echeverri; Carlos A Cañas; Gabriel J Tobón
Journal:  J Transl Autoimmun       Date:  2019-12-17

4.  Urinary Protein Array Analysis to Identify Key Inflammatory Markers in Children with IgA Vasculitis Nephritis.

Authors:  Julien Marro; Andrew J Chetwynd; Rachael D Wright; Silothabo Dliso; Louise Oni
Journal:  Children (Basel)       Date:  2022-04-27

5.  Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis.

Authors:  Abhishek Zanwar; Avinash Jain; Latika Gupta; Smirti Chaurasia; Sandeep Kumar; Durga Prasanna Misra; Ramnath Misra
Journal:  Clin Rheumatol       Date:  2018-07-11       Impact factor: 2.980

6.  Characterization of Urine Stem Cell-Derived Extracellular Vesicles Reveals B Cell Stimulating Cargo.

Authors:  Asmaa A Zidan; Mohammed Al-Hawwas; Griffith B Perkins; Ghada M Mourad; Catherine J M Stapledon; Larisa Bobrovskaya; Xin-Fu Zhou; Plinio R Hurtado
Journal:  Int J Mol Sci       Date:  2021-01-05       Impact factor: 5.923

Review 7.  Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus.

Authors:  Gongjun Tan; Binila Baby; Yuqiu Zhou; Tianfu Wu
Journal:  Front Immunol       Date:  2022-01-13       Impact factor: 7.561

Review 8.  Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature.

Authors:  Leonardo Palazzo; Julius Lindblom; Chandra Mohan; Ioannis Parodis
Journal:  J Clin Med       Date:  2022-09-28       Impact factor: 4.964

9.  New biomarkers in SLE: from bench to bedside.

Authors:  Riccardo Capecchi; Ilaria Puxeddu; Federico Pratesi; Paola Migliorini
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.